ZYME Zymeworks PE ratio, current and historical analysis
The current price-to-earnings ratio of ZYME can't be determined, as the TTM EPS of -$1.62 is negative. The most recent PE ratio recorded for Zymeworks was 1.96 in September 2023.
ZYME PE ratio history
Over the last seven years, the average PE ratio of Zymeworks has been 65.27. In the past seven years, ZYME's PE ratio reached its highest point in the Sep 2018 quarter at 314, with a price of $15.7 and an EPS of $0.05. The Sep 2023 quarter saw the lowest point at 1.96, with a price of $6.34 and an EPS of $3.24.
Zymeworks PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $14.64 | -$1.62 |
| 2023 | N/A | N/A | $10.39 | -$1.72 |
| 2022 | 4.12 | N/A | $7.86 | $1.91 |
| 2021 | N/A | N/A | $16.39 | -$4.11 |
| 2020 | N/A | N/A | $47.26 | -$3.58 |
| 2019 | N/A | N/A | $45.46 | -$3.83 |
| 2018 | N/A | N/A | $14.68 | -$1.26 |
| 2017 | N/A | N/A | $7.59 | -$0.51 |
| 2016 | N/A | N/A | N/A | -$2.65 |
| 2015 | N/A | N/A | N/A | -$1.7 |
| 2014 | N/A | N/A | N/A | -$1.77 |
Zymeworks PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Dec 2024 | N/A | N/A | $14.64 | -$1.62 |
| Sep 2024 | N/A | N/A | $12.55 | -$1.49 |
| Jun 2024 | N/A | N/A | $8.51 | -$1.51 |
| Mar 2024 | N/A | N/A | $10.52 | -$1.78 |
| Dec 2023 | N/A | N/A | $10.39 | -$1.72 |
| Sep 2023 | 1.96 | -33.56% | $6.34 | $3.24 |
| Jun 2023 | 2.95 | -11.14% | $8.64 | $2.93 |
| Mar 2023 | 3.32 | -19.42% | $9.04 | $2.72 |
| Dec 2022 | 4.12 | N/A | $7.86 | $1.91 |
| Sep 2022 | N/A | N/A | $6.15 | -$3.63 |
| Jun 2022 | N/A | N/A | $5.3 | -$4.08 |
| Mar 2022 | N/A | N/A | $6.55 | -$4.42 |
| Dec 2021 | N/A | N/A | $16.39 | -$4.11 |
| Sep 2021 | N/A | N/A | $29.04 | -$4.08 |
| Jun 2021 | N/A | N/A | $34.69 | -$4.34 |
ZYME average PE ratio chart
ZYME PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| ORMP Oramed Pharmaceuticals Inc | 23.82 | $105.62M |
| OLMA Olema Pharmaceuticals Inc | N/A | $248.1M |
| OMER Omeros Corp | N/A | $428.25M |
| ONVO Organovo Holdings Inc | N/A | $7.48M |
| ORIC Oric Pharmaceuticals Inc | N/A | $546.2M |
| ZYME Zymeworks Inc | N/A | $814.05M |
Frequently asked questions
What is Zymeworks's PE ratio?
The current price to earnings ratio of ZYME can't be calculated, as its EPS of -$1.62 is negative.
What is the highest PE ratio for ZYME?
Over the last seven years, the quarterly PE ratio reached a historic high of 314 in the Sep 2018 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from 
and Sharadar.